Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.74 |
| ▸ | HTR6 | P50406 | 5/20 | 0.74 |
| ▸ | HTR2A | P28223 | 10/20 | 0.73 |
| ▸ | HTR2C | P28335 | 4/20 | 0.73 |
| ▸ | HTR2B | P41595 | 3/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.65 |
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 3/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20970920 | 1.00 | HTR1A (0.74) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL30896267 | 0.92 | HTR2A (0.81) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL25439218 | 0.91 | SLC6A4 (0.75) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL23042909 | 0.89 | HTR2A (0.71) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| Iodide SCHEMBL30366641 | 0.88 | HTR2A (0.69) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL21073587 | 0.86 | HTR2A (0.68) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| Diethyltryptamine SCHEMBL517713 | 0.85 | HTR1A (1.00) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| N,N-Dimethyltryptamine SCHEMBL335710 | 0.85 | HTR2A (1.00) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| N,N-Dimethyltryptamine SCHEMBL29350959 | 0.85 | HTR2A (1.00) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| N,N-Dimethyltryptamine SCHEMBL27221709 | 0.85 | HTR2A (1.00) | HTR1AHTR6HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2022261263-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| EP-4704806-A1 | INJECTABLE PHARMACEUTICAL FORMULATIONS | Cybin IRL Limited (IE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | disclosed |
| EP-4583858-A1 | COMBINATIONS COMPRISING PSYCHEDELICS FOR THE TREATMENT OF SCHIZOPHRENIA AND OTHER NEUROPSYCHIATRIC AND NEUROLOGIC DISORDERS | Hadasit Medical Research Services&Development Ltd. (IL) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-4551212-A2 | TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4525916-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | Bexson Biomedical, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119497589-A | Therapeutic combinations, compositions and methods for designing and producing conditions that promote mental well-being | 心境设计实验室股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20230295086-A1 | NOVEL PSILOCIN DERIVATIVES HAVING PRODRUG PROPERTIES | HERCULES CAPITAL, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023122135-A1 | SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022236130-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | TURTLE BEAR HOLDINGS, LLC (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022221072-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | MYCRODOSE THERAPEUTICS INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022212789-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | MYCRODOSE THERAPEUTICS INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| EP-4061359-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | Turtle Bear Holdings, LLC (US) | 2022-09-28 | — | — | EP | disclosed |
| WO-2022115798-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115796-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022051670-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295086-A1 | NOVEL PSILOCIN DERIVATIVES HAVING PRODRUG PROPERTIES | HTR2A, HTR2C, HTR5A | HTR1A 5/4885HTR6 8/4885HTR2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.